Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

LEASES (Tables)

12 Months Ended

Dec. 31, 2023

The components of our operating lease expense were as follows (in thousands):


	Year Ended December 31,
	2023		2022		2021
Fixed operating lease expense	$	1,109	$	5,470	$	5,360
Variable operating lease expense		134		818		910
Total operating lease expense	$	1,243	$	6,288	$	6,270

Supplemental information related to our operating lease expense was as follows (in thousands):


	Year Ended December 31,
	2023		2022		2021
Cash payments included in the measurement of operating lease liabilities	$	1,534	$	10,485	$	10,082

Supplemental information related to our operating sublease was as follows (in thousands):

The following table presents the future minimum lease payments of our operating lease liabilities as of December 31, 2023 (in thousands):


For year ending December 31,
2024	$	739
2025		301
Total minimum payments required	$	1,040